By Reuters
August 18, 2025 – 7:48 AM PDT
(Reuters) – Novo Nordisk (NOVOb.CO) said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying type 2 diabetes patients in the United States.
Earlier this month, it said it expects continued competition from copycat versions of its blockbuster obesity drug Wegovy this year and rising pressure from main U.S. rival, Eli Lilly (LLY.N).
Novo said the new offer was part of its ongoing efforts to explore new collaborations and approaches towards improving access to authentic semaglutide medicines.
The offer will roll out across multiple platforms. Ozempic will be available through its NovoCare pharmacy program – launched earlier this year to sell Wegovy outside of insurance – for the first time, Novo said.
It also said it was partnering with telehealth service GoodRx (GDRX.O) to offer both Wegovy and Ozempic for $499 per month.
Novo said in April it was working with telehealth firms Ro and LifeMD (LFMD.O) to sell Wegovy to expand access to cash-paying patients.
Reporting by Sneha S K; Editing by Pooja Desai
What do YOU think? Click here to jump to the comments!Sponsored Content Below